drugset / Trial / NCT01271933

Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients

NCT01271933

Phase 3 Completed 441 enrolled Viatris Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia. All patients will receive pregabalin; half of the patients will receive placebo at some point in the study.

Timeline

Start
2011-03
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 330 mg
Subject Pregabalin Small molecule 495 mg

Indications